Browse Newsroom

InsuLife Appoints Former NASDAQ Vice Chairman to Advisory Board

December 21, 2021

InsuLife is pleased to announce the appointment of David Weild IV to our Advisory Board effective immediately. David Weild is a noted expert on capital markets and capital formation who has testified before the U.S. Congress at the House Subcommittee on Capital Markets and Government Sponsored Enterprises, the SEC, and in front of the 34-member nations and the European Commission for the Organization of Economic Co-operation and Development (OECD). 

Mr. Weild has served as Vice Chairman of The NASDAQ Stock Market in charge of the Corporate Client Division with line responsibility for NASDAQ's 4,000 listed companies.  He created NASDAQ's Market Intelligence Desk, Corporate Services Network and dual listings strategy which ultimately resulted in listing Charles Schwab and Hewlett Packard.  While at NASDAQ, Mr. Weild had the privilege of working with such luminaries as Howard Schultz (Starbucks), Tom Stemberg (Staples), Craig Barrett (Intel), Michael Dell (Dell Computer), Steve Jobs (Apple, Pixar, NeXT Computer) and others. 

Mr. Weild headed equity capital markets and corporate finance at a top-ten underwriter of IPOs and follow-on equity offerings.  During his career, he has participated in managing more than 1,000 public equity offering transactions. 

Mr. Weild holds an MBA from the Stern School of Business and a B.A. degree from Wesleyan University.  He also studied on exchange at The Sorbonne, Ecole des Haute Etudes Commerciales, and The Stockholm School of Economics.  Mr. Weild is former Treasurer of The Bond Club of New York.  

David holds FINRA Series 7, 24, 63, 79, 82 and 99 licenses.

“We are very pleased to have David join our board and look forward to benefiting from his extensive experience,” said Aage Naerdal, InsuLife Co-Founder and CEO.

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 spray-based insulin to market.
Learn More
© Copyright 2023 - InsuLife AS, All Rights Reserved
cross